Preparation of arbutin hydrogel formulation as green skin lightener formulation: in vitro and in vivo evaluation

A hydrogel formulation containing arbutin was developed for use as a topical cosmetic product aimed at enhancing the anti-melanogenesis effect and skin delivery. To develop Arbutin-hydrogel, 1% arbutin was incorporated into a Chitosan/alginate hydrogel. The impacts of biopolymer proportion on the arbutin-hydrogel preparations were investigated. Swelling analysis, weight loss analysis, differential scanning calorimetry (DSC), scanning electron microscopy (SEM), attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy, toxicity study and, skin absorption test were employed to assess the arbutin-hydrogel. The swelling percentages of arbutin-hydrogel increased significantly after 4 h. In vitro, cytotoxic activity revealed that arbutin-hydrogel has no toxicity. Also, the cutaneous penetration investigation revealed that arbutin-hydrogel had a superior cutaneous accumulation (42.25 ± 0.30%) compared to plain gel (16.80 ± 0.33%). Also, physico-chemical specifications assay and solid state assessment were employed to assess of optimum formulation. Arbutin-hydrogel (60.9 ± 1.68%) inhibited melanin formation more effectively than arbutin solution. In addition, arbutin-hydrogel exhibited a more inhibitory impact on L-dopa auto-oxidation (54.90 ± 2.26%) than arbutin solution (38.62 ± 2.26%). In addition, the Wistar rat cutaneous sensitivity testing demonstrated that the hydrogel component did not affect the epidermis. These outcomes demonstrated that the arbutin-hydrogel could potentially be utilized for Arbutin topical delivery, expanding the treatment options for hyperpigmentation disorders.